A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 197

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 317
Function: require_once

Metabolite phenotyping of kobusin and identification of glutathione conjugates with kobusin catechol metabolite. | LitMetric

Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We aimed to investigate the metabolic pathways of kobusin, a tetrahydrofurofuran lignan with benzo[1,3]dioxole group, which exhibits antioxidant, anti-inflammatory, and anticancer activities. The metabolic profiles of kobusin, following incubation with hepatocytes and human liver microsomes (HLMs), were categorized into three clusters using ion identity molecular networking, with each cluster subsequently linked by glucuronidation and sulfation. These clusters were predicted to correspond to demethylenation, demethylation, and methylation with demethylenation. The structures of the metabolites and the responsible metabolizing enzymes were further characterized using hepatocytes, HLMs, S9 fractions, cDNA-expressed cytochrome P450 isozymes (CYPs), UDP-glucuronosyltransferase isozymes (UGTs), and sulfotransferases (SULTs). Kobusin yielded five phase 1 metabolites, including kobusin catechol (M1) formed via CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5; O-desmethylkobusin (M2 and M3) via CYP2C9 and CYP2C19; and hydroxykobusin (M4 and M5) via CYP3A4/5. The major phase 1 metabolites (M1, M2, and M3) were subsequently converted into 14 phase 2 metabolites, including O-methyl-M1 (M6-M8) via catechol O-methyltransferase, as well as six glucuronide and sulfate conjugates of kobusin metabolites (M1-G, M2-G, M3-G, M6-G, M7-G, and M8-G; M1-S, M2-S, M3-S, M6-S, and M7-S) formed by UGTs and SULTs, respectively. Two glutathione (GSH) conjugates of the reactive intermediate derived from M1 (kobusin catechol) were identified after incubation of kobusin with HLMs in the presence of NADPH and GSH; however, these conjugates were not detected in hepatocyte incubations. In conclusion, kobusin undergoes extensive metabolism, yielding a total of 19 metabolites in human hepatocytes. These findings provide insight into the potential contributions of metabolizing enzymes to kobusin's pharmacokinetics and drug interactions associated with the reactive intermediate of M1.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2025.118255DOI Listing

Publication Analysis

Top Keywords

kobusin catechol
12
phase metabolites
12
kobusin
10
conjugates kobusin
8
metabolizing enzymes
8
metabolites including
8
cyp2c9 cyp2c19
8
gsh conjugates
8
reactive intermediate
8
metabolites
6

Similar Publications